Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Apellis Pharmaceuticals (APLS) over the last 4 years, with Jun 2025 value amounting to $126.0 million.

  • Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1.71% to $126.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $126.0 million, marking a year-over-year increase of 1.71%. This contributed to the annual value of $123.9 million for FY2024, which is 4.40% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Shares Outstanding (Diluted Average) of $126.0 million as of Q2 2025, which was up 0.46% from $125.5 million recorded in Q1 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $126.0 million during Q2 2025, and its lowest value of $80,654 during Q2 2021.
  • In the last 3 years, Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $123.4 million in 2024 and averaged $110.5 million.
  • Data for Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY surged of 111,797.21% (in 2023) over the last 5 years.
  • Over the past 5 years, Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $84.4 million in 2021, then rose by 25.70% to $106.1 million in 2022, then increased by 11.84% to $118.7 million in 2023, then climbed by 4.40% to $123.9 million in 2024, then rose by 1.71% to $126.0 million in 2025.
  • Its last three reported values are $126.0 million in Q2 2025, $125.5 million for Q1 2025, and $123.9 million during Q4 2024.